List Of 2024 Biotech Ipos
Last week, bladder cancer drug developer cg. The award for the biggest m&a deal of the first quarter of 2024 goes to gilead sciences, which acquired cymabay therapeutics for $4.43 billion in february,.
Sell shares in the coming days, they’ll mark the fourth and fifth biotech initial public offerings on us. Biotech m&a ended 2023 with a bang, but can investors expect the party to continue into 2024?